Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06211465Completed

Cardiovascular And Metabolic Risk After Arthroplasty

Role: collaborator

NCT05111379Unknown

Acute Local Metabolomic Alterations in Blood and Muscle Tissue in Intermittent Claudication

Role: collaborator

NCT04143386Unknown

Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease

Role: collaborator

NCT00487019Completed

Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment

Role: collaborator

All 4 trials loaded